<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481505</url>
  </required_header>
  <id_info>
    <org_study_id>CHL.1/02-2014</org_study_id>
    <secondary_id>2014-003778-17</secondary_id>
    <nct_id>NCT02481505</nct_id>
  </id_info>
  <brief_title>Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration.</brief_title>
  <official_title>Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration: a Prospective, Randomised, Observer-blind Study in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sintetica SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sintetica SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the effect of 3 doses of Chloroprocaine HCl 1% (30, 40 and 50 mg) for&#xD;
      spinal anaesthesia in adult patients undergoing short duration elective surgery of the lower&#xD;
      limb. Patients undergoing elective short-duration lower limb surgery will be randomised into&#xD;
      3 treatment groups (15 patients per group) to receive one of the 3 single doses of&#xD;
      Chloroprocaine HCl 1%, i.e. either D1, D2 or D3, via intrathecal injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy of the three Chloroprocaine HCl 1% doses (i.e. D1, D2 and D3) in&#xD;
      terms of time to complete regression of spinal block (i.e. end of anaesthesia)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Regression of Spinal Block</measure>
    <time_frame>Up to 5 hours after regression of two dermatomers</time_frame>
    <description>When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)</measure>
    <time_frame>Up to 40 min after spinal injection</time_frame>
    <description>Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Motor Block</measure>
    <time_frame>Up to 40 min after spinal injection</time_frame>
    <description>Time period from spinal injection (time 0 h) to achievement of motor block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Readiness for Surgery</measure>
    <time_frame>Up to 40 min after spinal injection</time_frame>
    <description>Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Regression of Spinal Block</measure>
    <time_frame>Up to 1 h and 40 min after readiness for surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Sensory Block to S1(Min)</measure>
    <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
    <description>Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Motor Block</measure>
    <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
    <description>Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Unassisted Ambulation</measure>
    <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
    <description>Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Block Metameric Level</measure>
    <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
    <description>Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Level of Sensory Block</measure>
    <time_frame>Up to 1 h and 40 min after readiness for surgery</time_frame>
    <description>Maximum metameric level of sensory block (decreased or absent sensation) achieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Level of Sensory Block</measure>
    <time_frame>Up to 1 h and 40 min after readiness for surgery</time_frame>
    <description>Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block</measure>
    <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
    <description>Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Eligibility for Home Discharge</measure>
    <time_frame>Expected up to 24 hrs post surgery</time_frame>
    <description>Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Spontaneous Urine Voiding</measure>
    <time_frame>Expected up to 24 hrs post surgery</time_frame>
    <description>Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Post-operative Analgesia</measure>
    <time_frame>Expected up to 24 hrs post surgery</time_frame>
    <description>Time from spinal injection (time 0 h) to first post-operative analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Administration of Rescue Anaesthesia or Rescue Analgesia</measure>
    <time_frame>Expected up to 24 hrs post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma</measure>
    <time_frame>at pre-dose, 5, 10, 30 and 60 min after spinal puncture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine</measure>
    <time_frame>at the time of first urine voiding post surgery</time_frame>
    <description>Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 6 +/- 1 after spinal puncture</time_frame>
    <description>All AEs occurring or worsening after the dose of IMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Neurological Symptoms (TNS)</measure>
    <time_frame>Up to Day 6 +/- 1 after spinal puncture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Assessment at the Site of Injection and at the Site of Surgery</measure>
    <time_frame>Up to Day 6 +/- 1 after spinal puncture</time_frame>
    <description>Number of patients with pain at the site of injection and at the site of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Expected up to 24 hrs post surgery</time_frame>
    <description>The following normal ranges Heart Rate parameters will be used:&#xD;
50-90 beats/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Expected up to 24 hrs post surgery</time_frame>
    <description>The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used:&#xD;
Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SpO2</measure>
    <time_frame>Expected up to 24 hrs post surgery</time_frame>
    <description>The following normal ranges SpO2 parameters will be used:&#xD;
Peripheral Oxygen Saturation: ≥ 95%</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Short Duration Lower Limb Surgery Via Spinal Anaesthesia</condition>
  <arm_group>
    <arm_group_label>3 mL Chloroprocaine HCl 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mL Chloroprocaine HCl 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mL Chloroprocaine HCl 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroprocaine HCl 1%</intervention_name>
    <description>Intrathecal Route</description>
    <arm_group_label>3 mL Chloroprocaine HCl 1%</arm_group_label>
    <arm_group_label>4 mL Chloroprocaine HCl 1%</arm_group_label>
    <arm_group_label>5 mL Chloroprocaine HCl 1%</arm_group_label>
    <other_name>Ampres 1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sex, age and surgery: male/female patients, 18-65 years old, scheduled for short&#xD;
             duration (less than 40 min) lower limb surgery requiring ≥ T12 metameric level of&#xD;
             sensory block&#xD;
&#xD;
          2. Body Mass Index (BMI): 18 - 32 kg/m2 inclusive&#xD;
&#xD;
          3. ASA physical status: I-II&#xD;
&#xD;
          4. Informed consent: signed written informed consent before inclusion in the study 5.&#xD;
             Full comprehension: ability to comprehend the full nature and purpose of the study,&#xD;
             including possible risks and side effects; ability to co-operate with the investigator&#xD;
             and to comply with the requirements of the entire study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physical findings: clinically significant abnormal physical findings which could&#xD;
             interfere with the objectives of the study. Contraindications to spinal anaesthesia.&#xD;
             History of neuromuscular diseases to the lower extremities&#xD;
&#xD;
          2. ASA physical status: III-V&#xD;
&#xD;
          3. Further anaesthesia: patients expected to require further anaesthesia&#xD;
&#xD;
          4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or&#xD;
             formulations ingredients; ascertained or presumptive hypersensitivity to the ester&#xD;
             type and major anaesthetics&#xD;
&#xD;
          5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular,&#xD;
             respiratory, skin, haematological, endocrine or neurological diseases that may&#xD;
             interfere with the aim of the study; ascertained psychiatric and neurological&#xD;
             diseases, sepsis, blood coagulation disorders, severe cardiopulmonary disease, thyroid&#xD;
             disease, diabetes or other neuropathies.&#xD;
&#xD;
          6. Investigative drug studies: participation in the evaluation of any investigational&#xD;
             product for 3 months before this study, calculated from the first day of the month&#xD;
             following the last visit of the previous study&#xD;
&#xD;
          7. Drug, alcohol: history of drug or alcohol abuse&#xD;
&#xD;
          8. Blood donation: blood donations in the 3 months before this study&#xD;
&#xD;
          9. Pregnancy and lactation: missing or positive pregnancy test at screening, pregnant or&#xD;
             lactating women&#xD;
&#xD;
         10. Chronic pain syndromes: patients with chronic pain syndromes (taking opioids,&#xD;
             antidepressants, anticonvulsant agents or chronic analgesic therapy) 11. Medications:&#xD;
             medication known to interfere with the extent of spinal blocks for 2 weeks before the&#xD;
             start of the study. Hormonal contraceptives for females are allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano MD Bonarelli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli, SC Anestesia e Terapia Intensiva post-operatoria e del dolore IOR-IRCCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stefano Bonarelli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <results_first_submitted>December 20, 2017</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 3, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02481505/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02481505/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
        <group group_id="P2">
          <title>4 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
        <group group_id="P3">
          <title>5 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
        <group group_id="B2">
          <title>4 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
        <group group_id="B3">
          <title>5 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0"/>
                    <measurement group_id="B2" value="0.0"/>
                    <measurement group_id="B3" value="0.0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="11.7"/>
                    <measurement group_id="B2" value="39.4" spread="12.5"/>
                    <measurement group_id="B3" value="41.5" spread="13.9"/>
                    <measurement group_id="B4" value="40.6" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Regression of Spinal Block</title>
        <description>When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)</description>
        <time_frame>Up to 5 hours after regression of two dermatomers</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Regression of Spinal Block</title>
          <description>When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" spread="12.1"/>
                    <measurement group_id="O2" value="39.4" spread="12.5"/>
                    <measurement group_id="O3" value="41.5" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)</title>
        <description>Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.</description>
        <time_frame>Up to 40 min after spinal injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)</title>
          <description>Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="3"/>
                    <measurement group_id="O2" value="6.6" spread="3.4"/>
                    <measurement group_id="O3" value="4.8" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Motor Block</title>
        <description>Time period from spinal injection (time 0 h) to achievement of motor block</description>
        <time_frame>Up to 40 min after spinal injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Motor Block</title>
          <description>Time period from spinal injection (time 0 h) to achievement of motor block</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.2"/>
                    <measurement group_id="O2" value="6" spread="3.3"/>
                    <measurement group_id="O3" value="4.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Readiness for Surgery</title>
        <description>Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12</description>
        <time_frame>Up to 40 min after spinal injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Readiness for Surgery</title>
          <description>Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="4.1"/>
                    <measurement group_id="O2" value="7.9" spread="4.7"/>
                    <measurement group_id="O3" value="5.3" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Regression of Spinal Block</title>
        <time_frame>Up to 1 h and 40 min after readiness for surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Regression of Spinal Block</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.761" spread="0.348"/>
                    <measurement group_id="O2" value="2.127" spread="0.457"/>
                    <measurement group_id="O3" value="2.229" spread="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Sensory Block to S1(Min)</title>
        <description>Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1</description>
        <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Sensory Block to S1(Min)</title>
          <description>Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.761" spread="0.348"/>
                    <measurement group_id="O2" value="2.127" spread="0.457"/>
                    <measurement group_id="O3" value="2.195" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Motor Block</title>
        <description>Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)</description>
        <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Motor Block</title>
          <description>Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.662" spread="0.789"/>
                    <measurement group_id="O2" value="3.361" spread="1.120"/>
                    <measurement group_id="O3" value="3.213" spread="0.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Unassisted Ambulation</title>
        <description>Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted</description>
        <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Unassisted Ambulation</title>
          <description>Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.662" spread="0.789"/>
                    <measurement group_id="O2" value="3.361" spread="1.120"/>
                    <measurement group_id="O3" value="3.213" spread="0.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Block Metameric Level</title>
        <description>Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1</description>
        <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Sensory Block Metameric Level</title>
          <description>Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Level of Sensory Block</title>
        <description>Maximum metameric level of sensory block (decreased or absent sensation) achieved</description>
        <time_frame>Up to 1 h and 40 min after readiness for surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Level of Sensory Block</title>
          <description>Maximum metameric level of sensory block (decreased or absent sensation) achieved</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Level of Sensory Block</title>
        <description>Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)</description>
        <time_frame>Up to 1 h and 40 min after readiness for surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Level of Sensory Block</title>
          <description>Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.224" spread="0.14"/>
                    <measurement group_id="O2" value="0.235" spread="0.077"/>
                    <measurement group_id="O3" value="0.234" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block</title>
        <description>Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block</description>
        <time_frame>Up to 5 h after regression of two dermatomers</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block</title>
          <description>Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.687" spread="0.361"/>
                    <measurement group_id="O2" value="0.851" spread="0.468"/>
                    <measurement group_id="O3" value="0.695" spread="0.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Eligibility for Home Discharge</title>
        <description>Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time</description>
        <time_frame>Expected up to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Eligibility for Home Discharge</title>
          <description>Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.021" spread="1.012"/>
                    <measurement group_id="O2" value="3.545" spread="1.281"/>
                    <measurement group_id="O3" value="3.530" spread="0.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Spontaneous Urine Voiding</title>
        <description>Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted</description>
        <time_frame>Expected up to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Spontaneous Urine Voiding</title>
          <description>Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.530" spread="0.761"/>
                    <measurement group_id="O2" value="3.361" spread="1.120"/>
                    <measurement group_id="O3" value="3.067" spread="0.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Post-operative Analgesia</title>
        <description>Time from spinal injection (time 0 h) to first post-operative analgesia</description>
        <time_frame>Expected up to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Post-operative Analgesia</title>
          <description>Time from spinal injection (time 0 h) to first post-operative analgesia</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.186" spread="10.815"/>
                    <measurement group_id="O2" value="2.928" spread="1.228"/>
                    <measurement group_id="O3" value="2.988" spread="1.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Administration of Rescue Anaesthesia or Rescue Analgesia</title>
        <time_frame>Expected up to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Administration of Rescue Anaesthesia or Rescue Analgesia</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.717" spread="0.397"/>
                    <measurement group_id="O2" value="0.315" spread="0.049"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma</title>
        <time_frame>at pre-dose, 5, 10, 30 and 60 min after spinal puncture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.127" spread="20.108"/>
                    <measurement group_id="O2" value="20.411" spread="23.037"/>
                    <measurement group_id="O3" value="24.887" spread="20.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.440" spread="31.778"/>
                    <measurement group_id="O2" value="38.851" spread="25.492"/>
                    <measurement group_id="O3" value="75.833" spread="67.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.459" spread="43.773"/>
                    <measurement group_id="O2" value="67.180" spread="36.899"/>
                    <measurement group_id="O3" value="97.647" spread="61.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.020" spread="41.381"/>
                    <measurement group_id="O2" value="53.093" spread="31.803"/>
                    <measurement group_id="O3" value="78.380" spread="48.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine</title>
        <description>Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted</description>
        <time_frame>at the time of first urine voiding post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine</title>
          <description>Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1217.7" spread="627.8"/>
                    <measurement group_id="O2" value="1827.9" spread="904.1"/>
                    <measurement group_id="O3" value="2103.5" spread="1537.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Adverse Events (TEAEs)</title>
        <description>All AEs occurring or worsening after the dose of IMP</description>
        <time_frame>Up to Day 6 +/- 1 after spinal puncture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Adverse Events (TEAEs)</title>
          <description>All AEs occurring or worsening after the dose of IMP</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Procedural pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transient Neurological Symptoms (TNS)</title>
        <time_frame>Up to Day 6 +/- 1 after spinal puncture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Transient Neurological Symptoms (TNS)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assessment at the Site of Injection and at the Site of Surgery</title>
        <description>Number of patients with pain at the site of injection and at the site of surgery</description>
        <time_frame>Up to Day 6 +/- 1 after spinal puncture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment at the Site of Injection and at the Site of Surgery</title>
          <description>Number of patients with pain at the site of injection and at the site of surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediately after regression of spinal block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>The following normal ranges Heart Rate parameters will be used:&#xD;
50-90 beats/min</description>
        <time_frame>Expected up to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>The following normal ranges Heart Rate parameters will be used:&#xD;
50-90 beats/min</description>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2" spread="8.5"/>
                    <measurement group_id="O2" value="67.5" spread="11.4"/>
                    <measurement group_id="O3" value="70.7" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1" spread="9.4"/>
                    <measurement group_id="O2" value="71" spread="14"/>
                    <measurement group_id="O3" value="71.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" spread="7"/>
                    <measurement group_id="O2" value="66.9" spread="10"/>
                    <measurement group_id="O3" value="67" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used:&#xD;
Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg</description>
        <time_frame>Expected up to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used:&#xD;
Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="12.9"/>
                    <measurement group_id="O2" value="126" spread="21.74"/>
                    <measurement group_id="O3" value="121.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.9" spread="10.5"/>
                    <measurement group_id="O2" value="127.9" spread="19.7"/>
                    <measurement group_id="O3" value="125.5" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.9" spread="10.9"/>
                    <measurement group_id="O2" value="124.7" spread="14.7"/>
                    <measurement group_id="O3" value="121.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" spread="12.1"/>
                    <measurement group_id="O2" value="78.9" spread="11.9"/>
                    <measurement group_id="O3" value="80.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="10.3"/>
                    <measurement group_id="O2" value="79.8" spread="10.9"/>
                    <measurement group_id="O3" value="79.1" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="12.2"/>
                    <measurement group_id="O2" value="79" spread="8.1"/>
                    <measurement group_id="O3" value="82" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SpO2</title>
        <description>The following normal ranges SpO2 parameters will be used:&#xD;
Peripheral Oxygen Saturation: ≥ 95%</description>
        <time_frame>Expected up to 24 hrs post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O2">
            <title>4 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
          <group group_id="O3">
            <title>5 mL Chloroprocaine HCl 1%</title>
            <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
          </group>
        </group_list>
        <measure>
          <title>SpO2</title>
          <description>The following normal ranges SpO2 parameters will be used:&#xD;
Peripheral Oxygen Saturation: ≥ 95%</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" spread="0.96"/>
                    <measurement group_id="O2" value="99.13" spread="1.25"/>
                    <measurement group_id="O3" value="98.53" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" spread="0.91"/>
                    <measurement group_id="O2" value="99.13" spread="0.83"/>
                    <measurement group_id="O3" value="98.53" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.33" spread="0.72"/>
                    <measurement group_id="O2" value="99.33" spread="0.90"/>
                    <measurement group_id="O3" value="99" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <desc>No SAEs and No subject discontinued for AEs</desc>
      <group_list>
        <group group_id="E1">
          <title>3 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
        <group group_id="E2">
          <title>4 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
        <group group_id="E3">
          <title>5 mL Chloroprocaine HCl 1%</title>
          <description>Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)&#xD;
Chloroprocaine HCl 1%: Intrathecal Route</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>diarrhoae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <description>The most frequent AE was procedural pain (verbatim: pain at the site of surgery)</description>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elisabetta Donati Clinical Project Leader</name_or_title>
      <organization>Sintetica SA, via Penate 5 Mendrisio</organization>
      <phone>+41.91.640.42.50</phone>
      <email>edonati@sintetica.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

